IL231387A - Predicting a cardiovascular risk event and its uses - Google Patents

Predicting a cardiovascular risk event and its uses

Info

Publication number
IL231387A
IL231387A IL231387A IL23138714A IL231387A IL 231387 A IL231387 A IL 231387A IL 231387 A IL231387 A IL 231387A IL 23138714 A IL23138714 A IL 23138714A IL 231387 A IL231387 A IL 231387A
Authority
IL
Israel
Prior art keywords
cardiovascular risk
risk event
event prediction
prediction
cardiovascular
Prior art date
Application number
IL231387A
Other languages
English (en)
Hebrew (he)
Other versions
IL231387A0 (en
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of IL231387A0 publication Critical patent/IL231387A0/en
Publication of IL231387A publication Critical patent/IL231387A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
IL231387A 2011-09-30 2014-03-06 Predicting a cardiovascular risk event and its uses IL231387A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30
PCT/US2012/058060 WO2013049674A1 (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Publications (2)

Publication Number Publication Date
IL231387A0 IL231387A0 (en) 2014-04-30
IL231387A true IL231387A (en) 2017-12-31

Family

ID=47993164

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231387A IL231387A (en) 2011-09-30 2014-03-06 Predicting a cardiovascular risk event and its uses

Country Status (16)

Country Link
US (3) US20130085079A1 (enExample)
EP (1) EP2761289B1 (enExample)
JP (3) JP6652781B2 (enExample)
KR (2) KR102248900B1 (enExample)
CN (4) CN107102151A (enExample)
AU (1) AU2013202112B9 (enExample)
BR (2) BR122019023720B1 (enExample)
CA (2) CA3074279C (enExample)
ES (1) ES2777002T3 (enExample)
IL (1) IL231387A (enExample)
IN (1) IN2014CN01970A (enExample)
MX (2) MX373248B (enExample)
RU (1) RU2651708C2 (enExample)
SG (3) SG10201607331WA (enExample)
WO (1) WO2013049674A1 (enExample)
ZA (1) ZA201401778B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20130171649A1 (en) * 2010-06-07 2013-07-04 Manuel Mayr Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
ES2629183T3 (es) 2011-03-10 2017-08-07 Somalogic, Inc. Aptámeros para diagnóstico de Clostridium difficile
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
HK1211624A1 (en) 2012-01-27 2016-05-27 The Board Of Trustees Of The University Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
CA2924987C (en) * 2013-09-24 2022-08-16 Somalogic, Inc. Multiaptamer target detection
SG11201607487UA (en) * 2014-03-21 2016-10-28 Sanofi Aventis Deutschland New markers for the assessment of the risk for development of a cardiovascular disorder
CA2949731A1 (en) * 2014-06-05 2015-12-10 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of an increased risk for mortality
AU2014407088B2 (en) * 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
US20210215711A1 (en) * 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
EP3426826A4 (en) * 2016-03-09 2019-09-04 Molecular Stethoscope, Inc. METHOD AND SYSTEMS FOR DETECTING TISSUE STATES
CN108780101A (zh) * 2016-04-06 2018-11-09 雀巢产品技术援助有限公司 用于预测体重减轻程度的生物标志物
CN108882872B (zh) 2016-04-15 2021-07-20 欧姆龙株式会社 生物体信息分析装置、生物体信息分析系统、程序以及生物体信息分析方法
CN105907857A (zh) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 一种用于动脉血栓的分子标记物和试剂及其应用
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
EP3279665B1 (en) * 2016-08-04 2020-07-08 Roche Diagniostics GmbH Circulating esm-1 (endocan) in the assessment of atrial fibrillation
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
ES2977423T3 (es) * 2017-12-13 2024-08-23 Hoffmann La Roche Angiopoyetina-2 (Ang-2) circulante y proteína de unión al factor de crecimiento insulínico 7 (IGFBP7) para la predicción de apoplejía
RU2685859C1 (ru) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития ишемического инсульта
CN109192250B (zh) * 2018-08-01 2021-12-07 华东理工大学 一种多相催化中克服表面物种快速迁移的加速模拟方法
KR20210044216A (ko) * 2018-08-10 2021-04-22 에프. 호프만-라 로슈 아게 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2)
US20210327540A1 (en) * 2018-08-17 2021-10-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
JP7333384B2 (ja) * 2018-08-22 2023-08-24 エフ． ホフマン－ラ ロシュ アーゲー 心房細動の評価における循環ｓｐｏｎ－１（スポンジン－１）
US20220187312A1 (en) * 2018-10-31 2022-06-16 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Biomarkers of subclinical atherosclerosis
KR102125053B1 (ko) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트
GB2612911B (en) 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
JP7712913B2 (ja) * 2019-09-03 2025-07-24 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
JP7510649B2 (ja) * 2019-11-06 2024-07-04 国立大学法人 香川大学 心不全マーカー
US10902955B1 (en) * 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
EP4153995A4 (en) * 2020-05-19 2024-10-23 Falcon Bioscience, LLC DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION ENGAGEMENT
FI130424B (en) * 2020-06-18 2023-08-23 Nightingale Health Oy Procedure for determining whether a subject has a disease or condition or whether the subject is at risk of developing a disease or condition
WO2022086913A2 (en) * 2020-10-20 2022-04-28 Somalogic Operating Co., Inc. Cardiovascular event risk prediction
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
WO2022165393A1 (en) * 2021-02-01 2022-08-04 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
EP4399723A4 (en) * 2021-08-26 2024-10-02 3P Healthcare Pty Ltd SYSTEM AND METHODS FOR ASSESSMENT OF CARDIOVASCULAR HEALTH AND RISK MANAGEMENT
US12412661B2 (en) 2021-11-25 2025-09-09 Samsung Electronics Co., Ltd. Electronic device and method of providing health guideline using the same
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
US20250259750A1 (en) * 2022-04-15 2025-08-14 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification
CN115932276B (zh) * 2022-12-07 2025-09-02 首都医科大学附属北京安贞医院 一种检测生物标志物的产品在制备急性心肌梗死或其并发症的诊断的产品中用途
WO2024226519A2 (en) * 2023-04-24 2024-10-31 Google Llc Deep learning-based photoplethysmography model for cardiovascular risk prediction

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2003094856A2 (en) * 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
EP1825265A4 (en) * 2004-12-10 2008-08-27 Univ Maryland AMYLOID SERUM PROTEIN USED AGAINST INFLAMMATION AND OBESITY
CN2783324Y (zh) * 2005-04-28 2006-05-24 穆海东 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2007086980A2 (en) * 2005-11-10 2007-08-02 Duke University Methods of determining the risk of developing coronary artery disease
US20090004673A1 (en) * 2006-01-31 2009-01-01 Mitsubishi Kagaku Iatron, Inc. Method for Determining Condition of Disseminated Intravascular Coagulation
EP2005168A4 (en) * 2006-03-09 2009-05-20 Biosite Inc METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
CN110372795A (zh) * 2007-08-02 2019-10-25 吉利德生物制剂公司 Lox和loxl2抑制剂及其应用
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
US20090186370A1 (en) * 2008-01-18 2009-07-23 Ogle Matthew F Diagnostic biomarkers for vascular aneurysm
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
JP2012500199A (ja) * 2008-08-11 2012-01-05 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 血管統合性を促進するマイクロ−ｒｎａおよびその使用
ES2795003T3 (es) * 2008-10-07 2020-11-20 Brahms Gmbh Biomarcador para la predicción de los primeros eventos adversos
AU2010259022B2 (en) * 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
CA2765145A1 (en) * 2009-06-15 2010-12-23 Cardiodx, Inc. Determination of coronary artery disease risk
JP2013509588A (ja) * 2009-10-29 2013-03-14 テシス バイオサイエンス， インコーポレイテッド ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー
WO2011072177A2 (en) * 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
EP2542266A4 (en) * 2010-03-03 2013-10-23 Somalogic Inc 4-1BB-BINDING APTAMERS AND USE THEREOF IN THE TREATMENT OF DISEASES AND DISORDERS
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
JP6124986B2 (ja) * 2012-03-19 2017-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 拡張期心不全を処置するための増殖分化因子（ｇｄｆ）

Also Published As

Publication number Publication date
SG11201400904SA (en) 2014-04-28
IN2014CN01970A (enExample) 2015-05-29
SG10201906900QA (en) 2019-09-27
US20200166523A1 (en) 2020-05-28
CA3074279C (en) 2021-10-19
KR20200055804A (ko) 2020-05-21
AU2013202112B2 (en) 2015-09-24
SG10201607331WA (en) 2016-11-29
MX2020004617A (es) 2020-08-06
EP2761289B1 (en) 2020-02-12
WO2013049674A1 (en) 2013-04-04
KR102248900B1 (ko) 2021-05-07
CA2847903A1 (en) 2013-04-04
CN107422126B (zh) 2020-03-27
US20150168423A1 (en) 2015-06-18
CN103959060A (zh) 2014-07-30
ES2777002T3 (es) 2020-08-03
EP2761289A1 (en) 2014-08-06
JP2018159713A (ja) 2018-10-11
CN114518458A (zh) 2022-05-20
RU2014110508A (ru) 2015-11-10
NZ622118A (en) 2016-01-29
BR112014007214A8 (pt) 2022-07-26
BR122019023720A2 (enExample) 2017-04-04
JP6652781B2 (ja) 2020-02-26
BR122019023720B1 (pt) 2023-01-24
CN107102151A (zh) 2017-08-29
EP2761289A4 (en) 2015-08-12
BR122019023720A8 (pt) 2022-07-26
CN103959060B (zh) 2017-05-17
JP2014528576A (ja) 2014-10-27
RU2651708C2 (ru) 2018-04-23
BR112014007214A2 (pt) 2017-04-04
AU2013202112B9 (en) 2015-10-22
KR102111624B1 (ko) 2020-05-18
KR20140084106A (ko) 2014-07-04
US20130085079A1 (en) 2013-04-04
JP2020024216A (ja) 2020-02-13
JP6917432B2 (ja) 2021-08-11
CN107422126A (zh) 2017-12-01
BR112014007214B1 (pt) 2022-08-16
CA2847903C (en) 2020-10-27
ZA201401778B (en) 2018-08-25
HK1247666A1 (zh) 2018-09-28
JP6546318B2 (ja) 2019-07-17
CA3074279A1 (en) 2013-04-04
MX2014003153A (es) 2014-04-30
IL231387A0 (en) 2014-04-30
AU2013202112A1 (en) 2013-05-02
MX373248B (es) 2020-05-11

Similar Documents

Publication Publication Date Title
ZA201401778B (en) Cardiovascular risk event prediction and uses thereof
IL233051B (en) Anti-phf-tau antibodies and uses thereof
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL229844B (en) Anti-psgl-1 antibodies and their use
EP2793894A4 (en) HETEROARYLE AND USES THEREOF
PL2822682T3 (pl) Mikrokapsułki i ich zastosowanie
GB201110783D0 (en) Methods and uses
GB201116774D0 (en) Uses and methods
PL2667710T3 (pl) Kompozycja owadobójcza i związane z nią sposoby
EP2716359A4 (en) COMPLEX AND USES THEREOF
SI2758532T1 (sl) Presejalni postopki in njihove uporabe
GB201111775D0 (en) Compounds and uses thereof
EP2712348A4 (en) DISTRIBUTOR AND METHODS
GB201108490D0 (en) Methods and uses
GB2504239B (en) Snap-hook
GB201114582D0 (en) Run around
GB201117881D0 (en) Biomarkers and uses thereof
GB201119443D0 (en) GoWinging Concept and patent
PT2734522T (pt) 4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk
GB201119123D0 (en) Interthermic and intrathermic spectroscopy
GB201121551D0 (en) Compounds and uses thereof
GB201121726D0 (en) Compounds and uses thereof
GB201117780D0 (en) Tool-lock karabiner
PL119176U1 (pl) Podręcznik
GB201105091D0 (en) Animated terms and conditions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed